Table 1. Meta-analysis of the association between Oct-4 expression and clinicopathological characteristics of NSCLC.
| Characteristics | N | No. samples | Heterogeneity (I2, P) | Model | OR (95% CI) | P value | Publication bias | Conclusion | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | PE | NE | Begg (P) | Egger (P) | |||||||
| Gender (male vs. female) | 10 | 943 | 470 | 473 | 0.0%, 0.999 | Fixed | 0.868 (0.650–1.159) | 0.337 | 0.371 | 0.273 | Not significant |
| Age (≥60 vs. <60 years) | 9 | 830 | 413 | 417 | 0.0%, 0.631 | Fixed | 1.033 (0.772–1.383) | 0.828 | – | – | Not significant |
| Smoking status (yes vs. no) | 4 | 408 | 214 | 194 | 0.0%, 0.907 | Fixed | 1.099 (0.711–1.700) | 0.671 | – | – | Not significant |
| Differentiation (G3 vs. G1 and G2) | 10 | 875 | 416 | 459 | 74.7%, <0.001 | Random | 3.065 (1.568–5.957) | 0.001 | 0.283 | 0.456 | Significant |
| TNM stage (III/IV vs. I/II) | 11 | 998 | 502 | 496 | 57.4%, 0.009 | Random | 3.695 (2.252–6.063) | <0.001 | 0.087 | 0.216 | Significant |
| Lymphatic metastasis (yes vs. no) | 9 | 965 | 455 | 510 | 60.1%, 0.010 | Random | 2.372 (1.504–3.742) | <0.001 | – | – | Significant |
| Histological subtypes (AC vs. SCC) | 9 | 788 | 405 | 383 | 63.8%, 0.005 | Random | 1.301 (0.749–2.261) | 0.351 | – | – | Not significant |
AC, adenocarcinoma; CI, confidence interval; NE, negative expression; NI, no information; NSCLC, non-small cell lung cancer; Oct-4, octamer-binding transcription factor 4; OR, odds ratio; PE, positive expression; SCC, squamous cell carcinoma.